Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women

• Endometrial Hyperplasia
• Osteoporosis

• Drug: Bazedoxifene/Conjugated Estrogen
  
  Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
• Drug: CE 0.45 mg/MPA 1.5mg
  
  Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
• Other: Placebo
  
  Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.

• Experimental: 1
  
  BZA 20mg/CE 0.625
  Intervention: Drug: Bazedoxifene/Conjugated Estrogen
• Experimental: Arm 2
  
  BZA 20mg/CE 0.45
  Intervention: Drug: Bazedoxifene/Conjugated Estrogen
• Active Comparator: Arm 3
  
  CE 0.45mg/MPA1.5mg
  Intervention: Drug: CE 0.45 mg/MPA 1.5mg
• Placebo Comparator: Arm 4
  
  Placebo
  Intervention: Other: Placebo

Inclusion Criteria:

• Generally healthy, postmenopausal women, aged 40 to less than 65 years
• Intact uterus
• At least 12 months of spontaneous amenorrhea, OR 6 months spontaneous amenorrhea with follicle-stimulating hormone (FSH) levels > 40 mIU/mL.

Exclusion Criteria:

• Use of oral estrogen-, progestin-, androgen-, or SERM-containing drug products within 8 weeks before screening (12 weeks for the osteoporosis substudy)
• A history or active presence of clinically important medical disease
• Malabsorption disorders